Head-To-Head Contrast: Aclarion (NASDAQ:ACON) vs. Grail (NASDAQ:GRAL)

Aclarion (NASDAQ:ACON) and Grail (NASDAQ:GRAL) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, dividends and valuation.

Valuation & Earnings

This table compares Aclarion and Grail’s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aclarion	$80,000.00	19.23	-$4.91 million	N/A	N/A
Grail	N/A	N/A	N/A	N/A	N/A

Grail has lower revenue, but higher earnings than Aclarion.

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Aclarion and Grail, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aclarion	0	0	1	0	3.00
Grail	0	0	0	0	N/A

Aclarion currently has a consensus price target of $1.50, suggesting a potential upside of 739.40%. Given Aclarion’s higher possible upside, research analysts plainly believe Aclarion is more favorable than Grail.

Profitability

This table compares Aclarion and Grail’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aclarion	-10,967.15%	-910.84%	-218.13%
Grail	N/A	N/A	N/A

Institutional and Insider Ownership

7.5% of Aclarion shares are held by institutional investors. 22.3% of Aclarion shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Aclarion beats Grail on 5 of the 8 factors compared between the two stocks.

About Aclarion

Aclarion, Inc., a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.

About Grail

GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.